PhotoPharmics Secures $6M Series B Funding to Illuminate New Therapies for Neurodegenerative Disorders

PhotoPharmics, Inc is thrilled to announce a successful funding round that raised $6,000,000, marking another major milestone in our ongoing commitment to transform the landscape of neurodegenerative disease treatment.

With over 30 years of groundbreaking research and experience, PhotoPharmics has distinguished itself as a trailblazer in the innovative field of treating neurodegenerative disorders through the eyes.

Our work centers on the development of specialized light solutions aimed at regulating circadian rhythms to combat conditions such as seasonal affective disorder, sleep disorders, anxiety, and depression—a legacy that began with our pioneering solutions later adopted by Philips-Respironics in 2007 and now enjoyed by millions worldwide.

Recognizing that many neurodegenerative diseases, including Parkinson’s disease, are accompanied by retinal deterioration and circadian system dysregulation, our dedicated research team has pushed the boundaries of traditional treatments by studying the therapeutic effects of specific wavelengths of light.

Pre-clinical animal research coupled with promising human pilot trials has demonstrated that timely, intensity-controlled light exposure can reduce Parkinson’s symptoms, paving the way for our pivotal human clinical trial.

The imminent publication of these trial results in Autumn 2018 underscores our commitment to rigorous scientific validation and patient safety.

The infusion of new capital will be strategically deployed to further refine our light delivery technologies, expand clinical trials, and accelerate the development of targeted interventions that could revolutionize how neurodegenerative disorders are managed.

This funding not only validates our innovative approach to health through ocular pathways but also fortifies our mission to improve quality of life for patients suffering from debilitating neurological conditions across the globe.